Please assess the completion status of the following clinical trial:

Trial Title: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infection~* CD4+/CD8+ T-cell count obtained within 30 days prior to study entry~* Confirmed or probable pulmonary or extrapulmonary TB (more information on the criterion can be found in the protocol)~* Chest x-ray within 30 days prior to study entry~* A PI-based antiretroviral regimen is required, as determined by the participant's primary clinician/clinical facility~* Certain laboratory values obtained within 14 days prior to study entry (more information on the criterion can be found in the protocol)~* For females of reproductive potential, negative serum or urine pregnancy test within 7 days prior to study entry and 72 hours of starting study medications~* Willing to use acceptable methods of contraception while on study drugs and for 6 weeks after stopping these drugs~* Karnofsky performance score \> 40 within 14 days prior to study entry, and likelihood of survival, in the opinion of the site investigator, for at least 6 months~* Ability to swallow oral medications~* Ability and willingness of participant or legal guardian/representative to provide informed consent~Exclusion Criteria:~* History of completed TB treatment and resolution of TB symptoms less than 1 year prior to the current TB episode at study entry, or incomplete treatment for a prior episode of TB (i.e., defaulted past TB treatment) at any time prior to the current TB episode~* Documented multidrug-resistant tuberculosis (MDR TB) or extensively drug-resistant tuberculosis (XDR TB)~* Participants infected with a rifamycin resistant strain of TB (more information on the criterion can be found in the protocol)~* Receipt of more than 28 cumulative days of anti-TB treatment for the current TB episode prior to study entry~* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements~* Active illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry, or that in the opinion of the site investigator, might otherwise interfere with adherence to study requirements~* Pregnant or breastfeeding~* Anticipated receipt of prohibited medications (more information on the criterion can be found in the protocol)~* Known intolerance/allergy/sensitivity or any hypersensitivity to components of study drugs or their formulations~* History of close contact with known MDR or XDR TB patients at any time prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Standard-dose LPV/r w/RBT (Type: EXPERIMENTAL): ART: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs).
- B: Double-dose LPV/r w/RIF (Type: ACTIVE_COMPARATOR): ART: lopinavir 800 mg/ritonavir 200 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, weight-based dosing for rifampin, ethambutol, and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs).
- C: Standard-Dose LPV/r w/RBT + RAL (Type: EXPERIMENTAL): ART: lopinavir 400 mg/ritonavir 100 mg twice daily + raltegravir 400 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility